[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session .

Keeping Pace with Advances in Myeloma

Program: Education Program
Saturday, December 8, 2012: 7:30 AM-9:00 AM
Hall B5, Level 1, Building B (Georgia World Congress Center)
Saturday, December 8, 2012: 4:00 PM-5:30 PM
Hall B5, Level 1, Building B (Georgia World Congress Center)
Keeping Pace with Advances in Myeloma Description:

This session will focus on recent advances in the understanding of multiple myeloma biology and the changes in the treatment of this disease after the introduction of the immunomodulatory drugs thalidomide and lenalidomide and the proteasome inhibitor bortezomib. The role of transplantation in the era of novel agents will be addressed, and future therapeutic directions will be discussed. This program will report on the most effective treatment strategies available today and outline how to properly integrate them in the management of multiple myeloma.

Dr. Gareth Morgan will review the biological features of multiple myeloma. He will describe the physiological immune system development, explain the mechanisms determining molecular alterations in myeloma, and correlate these abnormalities with the evolution of the disease. He will also comment on the clinical implications of these alterations in myeloma therapy.

Dr. S. Vincent Rajkumar will review the different doublet, triplet, or quadruplet drug combinations used for the treatment of newly diagnosed myeloma. He will provide efficacy and safety results of various studies and compare these approaches. He will also present preliminary results from recent studies introducing the concept of second-generation proteasome inhibitors.

Dr. Antonio Palumbo will review the role of stem cell transplantation in myeloma and the clinical benefit achieved after the introduction of novel induction, consolidation, and maintenance approaches. He will discuss whether drug combinations have replaced stem cell transplantation, the risk/benefit ratio of these approaches, and the role of maintenance treatment.

Gareth J. Morgan, MD PhD

Haemato-Oncology Unit, Royal Marsden Hospital, Sutton, United Kingdom

Antonio Palumbo, MD

Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy

See more of: Education Program